MAB21L4

Across TCGA pan-cancer cohorts, MAB21L4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAB21L4 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher MAB21L4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAB21L4 expression acts as an unfavorable survival marker.

UCS, LIHC, and SARC are the cancer types where MAB21L4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.102	0.688	<.001	36	view →
LIHC	OS	Median	All	0.198	0.777	.006	18	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
KIRP	OS	Median	All	0.635	0.903	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAB21L4–UCS (OS)

Open the UCS breakdown →